Aptuit prefers to operate behind the scenes. A pharmaceutical services company, Aptuit offers a range of support services to biotech and other drug development companies, including early- to late-stage development of pharmaceutical ingredients, clinical studies support, information systems development, project management, and consulting services. The company operates from more than a dozen offices in North America, Europe, and the Asia-Pacific region and serves companies of all sizes. Aptuit was founded in 2004; private equity firm Welsh, Carson, Anderson & Stowe holds a significant ownership stake in the company.

Paratek Pharmaceuticals Inc. company is working to create new forms of tetracycline that will be effective against newly resistant strains of bacteria and potentially treat diseases not associated with bacteria, including neurodegenerative and inflammatory conditions such as rheumatoid arthritis. It has synthesized more than 2,500 new tetracycline compounds and is sifting through each to find their possible applications. The company's Multiple Antibiotic Resistance Program (MAR) is looking at ways to genetically turn off bacteria's ability to survive, thereby preventing infection in the first place.

Scios Inc. company, a subsidiary of health care giant Johnson & Johnson, develops treatments targeting cardiovascular disease. Its flagship product Natrecor is an intravenously administered drug approved by the FDA for treating patients with acute heart failure who also experience shortness of breath with minimal activity. When the drug was introduced in 2001, it was the first new treatment for heart failure in more than 14 years. The drug is not without controversy, about both its long-term health effects and the company's marketing of it. Scios maintains the drug is safe and has launched a large clinical trial.

Omnicare Clinical Research is a contract research organization (CRO) offering drug development services, from Phase I to Phase IV clinical trials, to drug and medical device companies worldwide. A unit of nursing home pharmacy operator Omnicare, the CRO has special expertise in the area of geriatrics research and takes advantage of its parent's access to geriatric patient populations and investigators. However, the unit also provides support in numerous other therapeutic areas, including cardiovascular, dermatology, metabolism, and infectious disease. Services include patient and investigator recruitment, drug packaging and distribution, clinical trials management, and medical writing.

Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops a pipeline of Toll-like Receptor (TLR) product candidates. The Company's product candidates include HEPLISAV, a hepatitis B vaccine; SD-101, a Phase Ib hepatitis C therapy; DV-601, a Phase Ib hepatitis B therapy; Universal Flu vaccine, a preclinical vaccine under a supply and option agreement with Novartis; AZD1419, a preclinical asthma therapy partnered with AstraZeneca AB, and DV1079, a preclinical autoimmune and inflammatory disease therapy partnered with GlaxoSmithKline. In January 2010, the Company completed the acquisition of Symphony Dynamo, Inc. (SDI) from Symphony Dynamo Holdings LLC. Pursuant to the acquisition SDI became a wholly owned subsidiary of the Company.

Phenomix hopes to create a pharmaceutical phenomenon by investigating and discovering new treatments for immune system ailments and metabolic diseases. The drug development company's lead product candidate dutogliptin is an oral-dose treatment aiming to stabilize glucose levels in patients with Type 2 diabetes. Other pipeline candidates target infectious and autoimmune diseases, including hepatitis C and certain types of cancer. The biotechnology firm's drug candidates focus on inhibiting complex proteins (enzymes) that promote disease within the body. The company is owned by a number of private investors.

EquiTech Corporation company focuses on improving the effectiveness of commonly used drugs primarily by enhancing the absorbtion of the drugs. Its ZAG-1701 is a fast-acting ibuprofen pill designed to treat pain, including dental, fractural, and post-operative incision pain as well as migraines and other headaches. EquiTech has a strategic partnership with fellow Canadian company Ethypharm Inc., developer and manufacturer of drug delivery systems. EquiTech company was founded by chief scientific officer Fakhreddin Jamali after he discovered that absorption of pain medication is slowed when a patient is in pain.

EXACT Sciences Corporation company was founded in 1995 and is based in Madison, Wisconsin. Exact Sciences Corporation, a molecular diagnostics company, focuses on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Its non-invasive stool-based DNA (sDNA) screening technology includes proprietary and patented methods that isolate and analyze human DNA present in stool to screen for the presence of colorectal pre-cancer and cancer. The company's principal product includes ColoSure, a non-invasive laboratory developed stool-based DNA testing service for the detection of colorectal cancer in the average-risk population. Exact Sciences Corporation has strategic alliances with Laboratory Corporation of America Holdings, the MAYO Foundation for Medical Education and Research, and Genzyme Corporation.

Genzyme Biosurgery may turn you into the Six Million Dollar Man, but it can't do anything about your Six Million Dollar Medical Bill. The Genzyme Corp. division develops biotech products for orthopedic procedures. Top sellers include knee osteoarthritis treatment Synvisc and Carticel, which repairs damaged knee cartilage. Genzyme Biosurgery's biosurgical specialties unit makes Seprafilm, which prevents tissue adhesions after surgery. Other products include those to assist in adhesion prevention and hernia repair (Sepramesh) and severe burn treatment (Epicel).

Dechra lies down with dogs ... and cats and birds and horses too. Dechra Pharmaceuticals lays claim to being the only listed pharmaceutical company that makes most of its income from the animal health care market. The company manufactures and distributes veterinary pharmaceutical products and supplies internationally, mainly in the US and the UK. Its network of subsidiaries includes suppliers National Veterinary Services and Dechra Veterinary Products, manufacturer Dales Pharmaceuticals, and development companies North Western Laboratories and Cambridge Specialist Laboratory Services.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.